Q3 2018 EPS Estimates for Hologic, Inc. (HOLX) Increased by Analyst

Hologic, Inc. (NASDAQ:HOLX) – Jefferies Group boosted their Q3 2018 earnings per share estimates for shares of Hologic in a note issued to investors on Thursday. Jefferies Group analyst R. Denhoy now anticipates that the medical equipment provider will post earnings of $0.57 per share for the quarter, up from their prior estimate of $0.54. Jefferies Group also issued estimates for Hologic’s Q4 2018 earnings at $0.60 EPS, FY2018 earnings at $2.25 EPS, FY2019 earnings at $2.52 EPS and FY2020 earnings at $2.83 EPS.

Other research analysts have also issued reports about the company. Cowen raised Hologic to a “buy” rating and set a $52.00 price target for the company in a research report on Wednesday, December 20th. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target (up from $48.00) on shares of Hologic in a research report on Tuesday, January 9th. Bank of America raised Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price target for the company in a research report on Thursday, January 4th. Piper Jaffray Companies reissued a “buy” rating and issued a $48.00 price target on shares of Hologic in a research report on Thursday, November 9th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $48.00 price target on shares of Hologic in a research report on Friday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Hologic presently has a consensus rating of “Buy” and a consensus price target of $48.36.

Hologic (NASDAQ:HOLX) opened at $37.75 on Monday. The company has a market capitalization of $10,438.97, a price-to-earnings ratio of 9.96, a PEG ratio of 1.76 and a beta of 0.77. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. Hologic has a 1 year low of $35.33 and a 1 year high of $46.80.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.05. The firm had revenue of $791.10 million during the quarter, compared to analyst estimates of $785.80 million. Hologic had a return on equity of 20.75% and a net margin of 34.53%. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.52 EPS.

In related news, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $39.84, for a total transaction of $40,756.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.79% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Stanley Laman Group Ltd. increased its holdings in shares of Hologic by 4.7% in the fourth quarter. Stanley Laman Group Ltd. now owns 125,732 shares of the medical equipment provider’s stock valued at $5,375,000 after purchasing an additional 5,639 shares during the period. Ontario Teachers Pension Plan Board increased its holdings in shares of Hologic by 12.6% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 69,990 shares of the medical equipment provider’s stock valued at $2,992,000 after purchasing an additional 7,811 shares during the period. American International Group Inc. increased its holdings in shares of Hologic by 8.0% in the fourth quarter. American International Group Inc. now owns 107,449 shares of the medical equipment provider’s stock valued at $4,593,000 after purchasing an additional 7,982 shares during the period. TCW Group Inc. acquired a new position in shares of Hologic in the fourth quarter valued at about $547,000. Finally, Homrich & Berg acquired a new position in shares of Hologic in the fourth quarter valued at about $219,000. 92.77% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/12/q3-2018-eps-estimates-for-hologic-inc-holx-increased-by-analyst.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply